JP2018512380A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512380A5
JP2018512380A5 JP2017542486A JP2017542486A JP2018512380A5 JP 2018512380 A5 JP2018512380 A5 JP 2018512380A5 JP 2017542486 A JP2017542486 A JP 2017542486A JP 2017542486 A JP2017542486 A JP 2017542486A JP 2018512380 A5 JP2018512380 A5 JP 2018512380A5
Authority
JP
Japan
Prior art keywords
tumor antigen
individual
antigen peptides
cancer
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017542486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512380A (ja
JP6856534B2 (ja
Filing date
Publication date
Priority claimed from PCT/CN2015/074227 external-priority patent/WO2016145578A1/en
Application filed filed Critical
Publication of JP2018512380A publication Critical patent/JP2018512380A/ja
Publication of JP2018512380A5 publication Critical patent/JP2018512380A5/ja
Application granted granted Critical
Publication of JP6856534B2 publication Critical patent/JP6856534B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017542486A 2015-03-13 2016-03-11 活性化t細胞を用いるがん治療の方法 Active JP6856534B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2015/074227 2015-03-13
PCT/CN2015/074227 WO2016145578A1 (en) 2015-03-13 2015-03-13 Methods of cancer treatment using activated t cells
PCT/CN2016/076165 WO2016146035A1 (en) 2015-03-13 2016-03-11 Methods of cancer treatment using activated t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021009572A Division JP7244117B2 (ja) 2015-03-13 2021-01-25 活性化t細胞を用いるがん治療の方法

Publications (3)

Publication Number Publication Date
JP2018512380A JP2018512380A (ja) 2018-05-17
JP2018512380A5 true JP2018512380A5 (cg-RX-API-DMAC7.html) 2019-04-18
JP6856534B2 JP6856534B2 (ja) 2021-04-07

Family

ID=56918222

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017542486A Active JP6856534B2 (ja) 2015-03-13 2016-03-11 活性化t細胞を用いるがん治療の方法
JP2021009572A Active JP7244117B2 (ja) 2015-03-13 2021-01-25 活性化t細胞を用いるがん治療の方法
JP2022092917A Withdrawn JP2022111272A (ja) 2015-03-13 2022-06-08 活性化t細胞を用いるがん治療の方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021009572A Active JP7244117B2 (ja) 2015-03-13 2021-01-25 活性化t細胞を用いるがん治療の方法
JP2022092917A Withdrawn JP2022111272A (ja) 2015-03-13 2022-06-08 活性化t細胞を用いるがん治療の方法

Country Status (9)

Country Link
US (4) US10967054B2 (cg-RX-API-DMAC7.html)
EP (2) EP3268465B1 (cg-RX-API-DMAC7.html)
JP (3) JP6856534B2 (cg-RX-API-DMAC7.html)
KR (2) KR102698909B1 (cg-RX-API-DMAC7.html)
CN (3) CN115607659A (cg-RX-API-DMAC7.html)
CA (1) CA2975602A1 (cg-RX-API-DMAC7.html)
IL (2) IL253795B (cg-RX-API-DMAC7.html)
RU (1) RU2729362C2 (cg-RX-API-DMAC7.html)
WO (2) WO2016145578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
CN109715196A (zh) 2016-06-13 2019-05-03 转矩医疗股份有限公司 用于促进免疫细胞功能的组合物和方法
EP3525803B1 (en) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018071576A1 (en) * 2016-10-14 2018-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of tumors by inhibition of cd300f
JP7080458B2 (ja) * 2016-10-14 2022-06-06 国立大学法人京都大学 Pd-1経路阻害薬の薬剤感受性を判定する方法
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
WO2018098636A1 (zh) * 2016-11-29 2018-06-07 深圳华大基因研究院 多肽及其应用
WO2018102761A1 (en) * 2016-12-02 2018-06-07 City Of Hope Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
WO2018148381A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
US11293924B2 (en) * 2017-02-07 2022-04-05 Saitama Medical University Immunological biomarker for predicting clinical effect of cancer
AU2018218221A1 (en) * 2017-02-07 2019-08-15 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific T cells in adoptive immunotherapy
AU2018287169B2 (en) * 2017-06-22 2024-11-14 Neogap Therapeutics Ab T-cell expansion method and uses
KR102946326B1 (ko) * 2017-09-05 2026-03-31 시애틀 프로젝트 코포레이션 T-세포 요법을 위한 신생항원 동정
CA3074826A1 (en) 2017-09-05 2019-03-14 Torque Therapeutics, Inc. Therapeutic protein compositions and methods of making and using the same
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
EP3704268B1 (en) 2017-11-03 2025-01-22 Guardant Health, Inc. Normalizing tumor mutation burden
CA3081479A1 (en) * 2017-11-06 2019-05-09 Ludwig Institute For Cancer Research Ltd Method for expansion of lymphocytes
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US10363008B2 (en) * 2017-11-27 2019-07-30 Canon Medical Systems Usa, Inc. Computed tomography perfusion (CTP) method and apparatus using blood flow for discriminating types of cancer
WO2019105485A1 (zh) * 2017-12-01 2019-06-06 上海桀蒙生物技术有限公司 个性化癌症疫苗的制备方法
WO2019136155A1 (en) * 2018-01-08 2019-07-11 The Regents Of The University Of Michigan Aldh1 antigen-pulsed dendritic cells
WO2019183924A1 (en) * 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196087A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
WO2019196088A1 (en) * 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
CN112512538A (zh) * 2018-05-18 2021-03-16 国家儿童医疗中心 改进的靶向t细胞疗法
CN120193081A (zh) 2018-07-23 2025-06-24 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20210172961A1 (en) * 2018-07-27 2021-06-10 Board Of Regents, The University Of Texas System Methods for identifying rna editing-derived epitopes that elicit immune responses in cancer
CN109295106B (zh) * 2018-09-30 2020-07-24 北京鼎成肽源生物技术有限公司 一种hafft1细胞
CN109337873A (zh) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 一种lrff细胞
CN109294997B (zh) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 一种lrfft1细胞
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20220412979A1 (en) * 2018-10-29 2022-12-29 Genocea Biosciences, Inc. Treatment methods
US20220016205A1 (en) * 2018-11-21 2022-01-20 Board Of Regents, The University Of Texas System Methods of overcoming resistance to immune checkpoint inhibitors
CN113272419A (zh) * 2018-12-04 2021-08-17 南托米克斯有限责任公司 制备治疗性t淋巴细胞的方法
WO2020146434A2 (en) * 2019-01-07 2020-07-16 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
WO2020160285A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University SIRPα EXPRESSION ON T CELLS IS A BIOMARKER FOR FUNCTIONAL T CELLS DURING EXHAUSTION
CN113784725A (zh) * 2019-03-01 2021-12-10 弗洛制药公司 个性化癌症疫苗的设计、制造和用途
CN111751545A (zh) * 2019-03-28 2020-10-09 中国科学院上海药物研究所 一种筛选pd-l1/pd-1检测点抑制剂的方法
WO2020227279A1 (en) * 2019-05-06 2020-11-12 Hasumi International Research Foundation Therapy and methods of introducing immature dendritic cells and/or cytotoxic t lymphocyte and anti pd-1 / pd-l1 antibody for treatment of tumors
EP3989984A4 (en) * 2019-06-25 2024-05-22 City of Hope TREATMENT OF PDL1-POSITIVE TUMORS WITH NK CELLS
US20220378872A1 (en) * 2019-10-31 2022-12-01 Fukushima Medical University Composition for treatment and/or prevention of tumor
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
CN111337681A (zh) * 2020-03-20 2020-06-26 上海东方肝胆外科医院 评估肝细胞癌预后的标志物、试剂盒及方法
AU2021262547A1 (en) * 2020-04-28 2022-11-10 Achilles Therapeutics Uk Limited T cell therapy
AU2021264068A1 (en) * 2020-04-30 2022-12-08 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
CN111575232A (zh) * 2020-05-15 2020-08-25 暨南大学 JQ1在抑制T淋巴细胞PD-1和/或Tim-3表达中的应用
CN111647563A (zh) * 2020-08-06 2020-09-11 北京翊博普惠生物科技发展有限公司 靶向Survivin全抗原的DC细胞、CTL细胞及其制备方法和应用
JPWO2022059780A1 (cg-RX-API-DMAC7.html) * 2020-09-18 2022-03-24
CN112501308B (zh) * 2020-11-30 2025-10-10 中国水产科学研究院珠江水产研究所 一组鳖科动物线粒体全基因组扩增通用引物
CN114133440B (zh) * 2021-03-24 2024-12-06 深圳市新靶向生物科技有限公司 一种与乳腺癌驱动基因突变相关的抗原肽组合及其应用
CN117881794A (zh) * 2021-06-30 2024-04-12 诺瓦瑟拉姆株式会社 制备包含血中循环肿瘤细胞的试样的方法
WO2023072877A1 (en) * 2021-10-25 2023-05-04 Ellennbe Gmbh Pharmaceutical composition and kit comprising an immunomodulatory substance for treating diseases
KR102732912B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732913B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 흑색종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732909B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732910B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
KR102732911B1 (ko) * 2021-12-29 2024-11-20 의료법인 명지의료재단 K-ras 특이적 활성화 T 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법
CN117143816A (zh) * 2022-05-24 2023-12-01 北京纬晓生物技术开发有限责任公司 一种自体卵巢癌杀伤细胞及其制备方法和其应用
CN115998851A (zh) * 2022-12-28 2023-04-25 四川康德赛医疗科技有限公司 一种个体化mRNA组合物、载体、mRNA疫苗及其应用
WO2026085050A1 (en) * 2024-10-15 2026-04-23 Immunitybio, Inc. Dual-specific binding molecule useful for isolating specific blood cells
EP4752217A1 (en) * 2024-11-28 2026-06-03 invIOs GmbH Manufacturing method for activated lymphocytes
CN121243357A (zh) * 2025-11-18 2026-01-02 吉林大学第一医院 一种肿瘤疫苗及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5388946A (en) 1988-01-20 1995-02-14 Grau Gmbh & Co. Systems and methods for the automated archiving and retrieval of computer data storage cassettes
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
JP2000505650A (ja) * 1996-02-08 2000-05-16 アメリカ合衆国 樹状突起細胞を形質転換し、そしてt細胞を活性化するための方法及び組成物
US20050170503A1 (en) * 1997-02-27 2005-08-04 University Of Pittsburgh In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens
US20040110283A1 (en) 1997-02-27 2004-06-10 University Of Pittsburgh Of The Commonwealth System Of Higher Education Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products
CN1353575A (zh) * 1999-03-31 2002-06-12 匹兹堡大学联邦制高等教育 用树状细胞一肿瘤细胞或树状细胞一病毒细胞衍生的免疫原在体外诱导抗原特异性t-销细胞
US7988963B1 (en) 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
WO2002087627A1 (en) * 2001-04-27 2002-11-07 Xcyte Therapies, Inc. Maturation of antigen-presenting cells using activated t cells
EP1957634A4 (en) 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc COMPOSITIONS AND METHODS OF INDUCING THE ACTIVATION OF UNREFERENCE MONOCYTIC DENDRITE CELLS
AU2008323853B8 (en) 2007-11-08 2014-07-24 Beth Israel Deaconess Medical Center Stimulation of anti-tumor immunity using dendritic cell/tumor cell fusions and anti-CD3/CD28
DK2271767T3 (en) 2008-04-03 2016-08-29 Cb Biotechnologies Inc Amplikonredning-multiplex polymerase chain reaction for the amplification of multiple target
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
US9211321B2 (en) 2009-10-27 2015-12-15 Immunicum Ab Method for proliferation of antigen-specific T cells
CN104411331B (zh) * 2012-01-13 2018-08-21 哈佛学院董事会 在结构聚合装置中tlr激动剂的控制传递
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
WO2016154628A1 (en) 2015-03-26 2016-09-29 Xiuli Wang Bi-specific targeted chimeric antigen receptor t cells
US20180171294A1 (en) 2015-03-26 2018-06-21 The Trustees Of The University Of Pennsylvania In vitro artificial lymph node method for sensitization and expansion of t cells for therapy and epitope mapping
CN104946588A (zh) 2015-07-07 2015-09-30 英普乐孚生物技术(上海)有限公司 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法
CN106645677B (zh) 2016-11-15 2019-08-09 恒瑞源正(上海)生物科技有限公司 体外检测肿瘤新生抗原特异性t细胞的方法、试剂盒以及肿瘤疫苗
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells

Similar Documents

Publication Publication Date Title
Chaurio et al. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures
RU2017134270A (ru) Способы лечения рака с применением активированных t-клеток
Xue et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy
Tang et al. Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives
D’Alise et al. Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection
Kooreman et al. Autologous iPSC-based vaccines elicit anti-tumor responses in vivo
Ye et al. An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ
Parkhurst et al. Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression
Marigo et al. T cell cancer therapy requires CD40-CD40L activation of tumor necrosis factor and inducible nitric-oxide-synthase-producing dendritic cells
Matsuzaki et al. Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses
Palucka et al. Taming cancer by inducing immunity via dendritic cells
Xie et al. The emerging role of dendritic cells in the tumor microenvironment: from antigen presentation to targeted immunotherapy
Boudreau et al. Engineering dendritic cells to enhance cancer immunotherapy
Butler et al. Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Weinstock et al. Dendritic cell therapies for hematologic malignancies
KR102229421B1 (ko) 항원-특이적 t 세포 식별, 농축, 및/또는 증식을 위한 시약 및 방법
JP2021520849A5 (cg-RX-API-DMAC7.html)
CN102597222B (zh) 用于增殖抗原特异性t细胞的方法
Ochi et al. Optimization of T-cell reactivity by exploiting TCR chain centricity for the purpose of safe and effective antitumor TCR gene therapy
Sonntag et al. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report
Borges et al. Trial watch: anticancer vaccination with dendritic cells
Giannakopoulou et al. AT cell receptor targeting a recurrent driver mutation in FLT3 mediates elimination of primary human acute myeloid leukemia in vivo
JP2022513148A (ja) T細胞の改変
Straetemans et al. TCR Gene Transfer: MAGE‐C2/HLA‐A2 and MAGE‐A3/HLA‐DP4 Epitopes as Melanoma‐Specific Immune Targets
Sundarasetty et al. Lentivirus-induced dendritic cells for immunization against high-risk WT1+ acute myeloid leukemia